Clinical Trial Update: A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease [Phase 3]

View source ↗

Summary

Phase 3 trial comparing finerenone to a fixed-dose combination of torsemide and spironolactone in hypertension with chronic kidney disease is currently recruiti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Hypertension

Drugs mentioned

• Aldactone (spironolactone)
• Demadex (torsemide)
• Kerendia (finerenone)

Snippet

Sponsor: Sarfez Pharmaceuticals, Inc. | Conditions: Hypertension (HTN) | Phase 3 | Status: RECRUITING